NIHR awards COVID-19 antiviral trial funding to University of Oxford
- 27 October 2021
- 1 min read
The National Institute for Health Research (NIHR) has awarded funding to the University of Oxford - working with several UK universities - to carry out a first-of-its-kind clinical trial, testing novel antiviral COVID-19 treatments for use early on in the illness, by people in the community with COVID-19 who are at higher risk of complications.
The Platform Adaptive trial of NOvel antiviRals for eArly treatMent of COVID-19 In the Community (PANORAMIC) is a national priority trial, and as soon as it is set up for delivery - will be open to eligible participants from across the UK.
PANORAMIC has been designed as a ‘platform clinical trial’, meaning it can rapidly evaluate several antiviral treatments over time that could help people at high risk of COVID-19 recover sooner, prevent the need for hospital admission and so ease the burden on the NHS.
